Adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis associated with Ozempic, Wegovy, and Rybelsus, the three popular GLP-1 receptor agonists containing semaglutide used as weight-loss drugs, are relatively well-known by now. In comparison, Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects have not received much attention.
Remarkably, medical researchers found that semaglutide — and therefore Wegovy, Rybelsus, and Ozempic — increased the risk of deep vein thrombosis (DVT) by 266% in patients with type 2 diabetes. The medical journal article that reported this semaglutide DVT side effect finding is “Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials”, published by the Endocrine Journal back in 2021.
Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects are particularly alarming since patients who have type 2 diabetes and who are obese are already at an increased risk of DVT. Significantly, the authors of this 2021 Endocrine Journal article suggested that Ozempic, Rybelsus, and Wegovy perhaps should be avoided by obese people with type 2 diabetes patients due to this semaglutide DVT side effect finding.
Here is some medical information about deep vein thrombosis (also known as deep venous thrombosis) from the Mayo Clinic, the U.S. National Institute of Health’s Medline Plus, and the Centers for Disease Control and Prevention.
We are investigating possible drug injury lawsuits involving Wegovy, Rybelsus, and Ozempic deep vein thrombosis side effects.[Read article in full at original source]
Strictly Confidential, No Obligation